These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 18392923)
1. Use of palliative radiotherapy trials for clinical biomarker development. Wan J; Milosevic M; Brade AM Cancer Metastasis Rev; 2008 Sep; 27(3):435-43. PubMed ID: 18392923 [TBL] [Abstract][Full Text] [Related]
2. Further radiobiologic modeling of palliative radiotherapy: use of virtual trials. Jones B; Dale RG Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):221-9. PubMed ID: 17707276 [TBL] [Abstract][Full Text] [Related]
3. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs. Chen AY; Chou R; Shih SJ; Lau D; Gandara D Crit Rev Oncol Hematol; 2004 May; 50(2):111-9. PubMed ID: 15157660 [TBL] [Abstract][Full Text] [Related]
4. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Shi Q; Mandrekar SJ; Sargent DJ Scand J Gastroenterol; 2012 Mar; 47(3):356-62. PubMed ID: 22181041 [TBL] [Abstract][Full Text] [Related]
5. The NCI All Ireland Cancer Conference. Johnston PG; Daly PA; Liu E Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862 [TBL] [Abstract][Full Text] [Related]
6. The role of palliative radiotherapy in advanced head and neck cancer. Hodson DI; Bruera E; Eapen L; Groome P; Keane T; Larsson S; Pearcey R Can J Oncol; 1996 Feb; 6 Suppl 1():54-60. PubMed ID: 8853539 [TBL] [Abstract][Full Text] [Related]
7. How should we design trials of palliative radiotherapy? Kirkbride P Can J Oncol; 1996 Feb; 6 Suppl 1():95-7. PubMed ID: 8853545 [TBL] [Abstract][Full Text] [Related]
8. Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. Priestman TJ Can J Oncol; 1996 Feb; 6 Suppl 1():17-22. PubMed ID: 8853534 [TBL] [Abstract][Full Text] [Related]
9. Ethical aspects of patient information in radiation oncology. An introduction and a review of the literature. Schäfer C; Herbst M Strahlenther Onkol; 2003 Jul; 179(7):431-40. PubMed ID: 12835879 [TBL] [Abstract][Full Text] [Related]
10. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. Dhani N; Siu LL Cancer Metastasis Rev; 2008 Sep; 27(3):339-49. PubMed ID: 18379730 [TBL] [Abstract][Full Text] [Related]
11. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective. Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210 [TBL] [Abstract][Full Text] [Related]
13. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1. Lunsford LD; Flickinger JC; Larson D Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030 [TBL] [Abstract][Full Text] [Related]
14. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Lee JW; Figeys D; Vasilescu J Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683 [TBL] [Abstract][Full Text] [Related]
15. A review of hypofractionated palliative radiotherapy. Lutz ST; Chow EL; Hartsell WF; Konski AA Cancer; 2007 Apr; 109(8):1462-70. PubMed ID: 17330854 [TBL] [Abstract][Full Text] [Related]
16. Measuring the cost of palliative radiotherapy. Warde P; Murphy T Can J Oncol; 1996 Feb; 6 Suppl 1():90-4. PubMed ID: 8853544 [TBL] [Abstract][Full Text] [Related]
17. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. Riesterer O; Milas L; Ang KK J Clin Oncol; 2007 Sep; 25(26):4075-83. PubMed ID: 17827456 [TBL] [Abstract][Full Text] [Related]
18. Palliation and supportive care in radiation medicine. Janjan N Hematol Oncol Clin North Am; 2006 Feb; 20(1):187-211. PubMed ID: 16580563 [TBL] [Abstract][Full Text] [Related]